Burning Rock Biotech Limited (BNR) saw its shares surge 6.23% in pre-market trading on Wednesday, following the release of its third quarter 2024 financial results.
The company reported revenue growth and margin expansion across its business segments. Total revenue increased 0.8% year-over-year to RMB128.6 million ($18.3 million), driven by a 17% increase in revenue from the in-hospital business and a 27.1% rise in pharma research and development services revenue.
Gross margins also improved significantly, with the company's overall gross margin rising to 71.4% from 67.4% a year ago. Non-GAAP gross margin reached 76%, compared to 74.5% in the prior-year period.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。